Valuation: Insmed Incorporated

Market Cap 24.93B 22.14B 20.7B 18.87B 35.52B 2,400B 36.01B 250B 96.96B 1,222B 93.58B 91.56B 3,926B P/E 2026 *
-70x
P/E 2027 * 164x
Enterprise Value 24.29B 21.58B 20.18B 18.39B 34.62B 2,339B 35.1B 244B 94.5B 1,191B 91.21B 89.24B 3,826B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 8.27x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-3.72%
1 week-9.32%
Current month-3.43%
1 month-9.29%
3 months+3.01%
6 months-33.14%
Current year-36.67%
1 week 109.71
Extreme 109.71
122.9
1 month 109.71
Extreme 109.71
130.83
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Sell

Director

-25,000 0.0114%
8/17/26 A Sell

Director

-5,000 0.0023%
8/10/26 A Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-3.74%-9.32%-25.16%+334.45% 24.93B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.63%-4.87%+28.39%+34.95% 44.25B
+1.15%+3.88%+352.71%+693.33% 43.99B
-1.55%+0.08%+7.49%+101.83% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-1.22%-2.22%-5.04%-13.92% 24.69B
Average +0.15%+1.75%+48.78%+143.24% 42.15B
Weighted average by Cap. +0.36%+1.71%+55.27%+142.17%

Financials

2026 *2027 *
Net sales 1.81B 1.61B 1.5B 1.37B 2.58B 174B 2.61B 18.17B 7.03B 88.66B 6.79B 6.64B 285B 2.88B 2.55B 2.39B 2.18B 4.1B 277B 4.15B 28.9B 11.19B 141B 10.8B 10.56B 453B
Net income -350M -311M -291M -265M -498M -33.68B -505M -3.51B -1.36B -17.15B -1.31B -1.28B -55.09B 182M 161M 151M 137M 259M 17.49B 262M 1.83B 707M 8.91B 682M 667M 28.61B
Net Debt -632M -561M -525M -478M -900M -60.83B -913M -6.35B -2.46B -30.98B -2.37B -2.32B -99.51B -1.16B -1.03B -961M -875M -1.65B -111B -1.67B -11.62B -4.5B -56.71B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
01/10/26 $110.34 -3.33% 1,408,725
30/09/26 $114.14 -1.29% 2,870,338
29/09/26 $115.63 -1.73% 1,668,367
28/09/26 $117.67 -0.14% 1,744,370
25/09/26 $117.83 -3.06% 2,672,745
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
114.14USD
Average target price
197.74USD
Spread / Average Target
+73.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock